amg900  (ApexBio)

Journal: bioRxiv

Article Title: MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality

doi: 10.1101/2023.11.07.565938

Figure Lengend Snippet: RPE-NEO and RPE-MYC cells were treated with either vehicle control (0.1% DMSO) or indicated mitotic inhibitors for 24 h before immunofluorescent staining for H3Ser10P and staining for DNA with 4’,6-diamidino-2-phenylindole (DAPI). Cells positive for H3Ser10P were scored as mitotic cells and quantified when cells were treated with compounds other than AURKB inhibitors. For cells exposed to AZD1152 and AMG900, mitotic cells were identified based on their condensed chromosomes revealed by DAPI staining. The following mitotic inhibitors were used at minimally effective concentrations that are known to inhibit their respective targets, AZD1152 (200 nM), AMG900 (10 nM), BAY1217389 (20 nM), Centrinone (1 μM), GSK923295 (40 nM), SB743921 HCl (1.25 nM), Sovilnesib (80 nM). (A) Representative immunofluorescent images. (B) The percentage of the mitotic cells. Data are presented as mean ± SD. ****p<0.0001. (C) Histograms show the ratio of the mitotic index (MI) in RPE-MYC cells relative to RPE- NEO cells.

Article Snippet: Other antimitotic agents were obtained from the following commercial sources, AZD1152 (Selleck, CAS: 722544-51-6, Cat. No. S1147), AMG900 (TargetMol, CAS: 945595-80-2, Cat. No. T6380), BAY1217389 (Selleck, CAS: 1554458-53-5, Cat. No. S8215), Centrinone (TargetMol, CAS: 1798871-30-3,Cat.

Techniques: Staining

Journal: Frontiers in Oncology

Article Title: Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers

doi: 10.3389/fonc.2022.965261

Figure Lengend Snippet: Investigational drugs in well differentiated and dedifferentiated liposarcoma.

Article Snippet: AMG900 (Amgen) , AURKA/B , Phase I in advanced solid tumors and AML , ( ) .

Techniques: Binding Assay

Journal: Cancer cell

Article Title: Poziotinib for EGFR exon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity

doi: 10.1016/j.ccell.2022.06.006

Figure Lengend Snippet: Key Resource Table

Article Snippet: AMG900 , Selleck Chem , S2719.

Techniques: Produced, Virus, Clinical Proteomics, Recombinant, Viability Assay, Lysis, In Vitro, In Vivo, Gene Expression, Mutagenesis, Software